An antibody therapy markedly reduces aggregates of amyloid-β, the hallmark protein of Alzheimer's disease, and might slow cognitive decline in patients. Confirmation of a cognitive benefit would be a game-changer. See Article p.50
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A one-two punch targeting reactive oxygen species and fibril for rescuing Alzheimer’s disease
Nature Communications Open Access 24 January 2024
-
Opening the debate on deep brain stimulation for Alzheimer disease – a critical evaluation of rationale, shortcomings, and ethical justification
BMC Medical Ethics Open Access 11 June 2018
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
References
Selkoe, D. J. & Hardy, J. EMBO Mol. Med. 8, 595–608 (2016).
Sevigny, J. et al. Nature 537, 50–56 (2016).
Haass, C. & Selkoe, D. J. Nature Rev. Mol. Cell Biol. 8, 101–112 (2007).
Reiman, E. M. et al. Nature Rev. Neurol. 12, 56–61 (2016).
Fleisher, A. S. et al. JAMA Neurol. 72, 316–324 (2015).
Yu, J. Y. & Watts, R. J. Neurotherapeutics 10, 459–472 (2013).
Sperling, R. A. et al. Alzheimer's Dement. 7, 367–385 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.M.R. is a principal investigator of the Alzheimer’s Prevention Initiative (API), which is involved in the evaluation of anti-Aβ and other promising Alzheimer’s prevention therapies.
Related links
Rights and permissions
About this article
Cite this article
Reiman, E. Attack on amyloid-β protein. Nature 537, 36–37 (2016). https://doi.org/10.1038/537036a
Published:
Issue Date:
DOI: https://doi.org/10.1038/537036a
This article is cited by
-
A one-two punch targeting reactive oxygen species and fibril for rescuing Alzheimer’s disease
Nature Communications (2024)
-
Drug trial for Alzheimer’s disease is a game changer
Nature (2023)
-
Anti-diabetic vanadyl complexes reduced Alzheimer’s disease pathology independent of amyloid plaque deposition
Science China Life Sciences (2019)
-
Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer’s disease therapy
Biophysical Reviews (2019)
-
Opening the debate on deep brain stimulation for Alzheimer disease – a critical evaluation of rationale, shortcomings, and ethical justification
BMC Medical Ethics (2018)
